Cargando…
SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272402/ https://www.ncbi.nlm.nih.gov/pubmed/37334365 http://dx.doi.org/10.3389/fimmu.2023.1107576 |
_version_ | 1785059485984751616 |
---|---|
author | Lim Kam Sian, Terry C. C. Goncalves, Gabriel Steele, Joel R. Shamekhi, Tima Bramberger, Liesl Jin, Dongbin Shahbazy, Mohammad Purcell, Anthony W. Ramarathinam, Sri Stoychev, Stoyan Faridi, Pouya |
author_facet | Lim Kam Sian, Terry C. C. Goncalves, Gabriel Steele, Joel R. Shamekhi, Tima Bramberger, Liesl Jin, Dongbin Shahbazy, Mohammad Purcell, Anthony W. Ramarathinam, Sri Stoychev, Stoyan Faridi, Pouya |
author_sort | Lim Kam Sian, Terry C. C. |
collection | PubMed |
description | Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such as vaccines and T-cell therapies. Hence, a comprehensive understanding and profiling of the immunopeptidome is required to foster the growth of these personalised solutions. We herein describe SAPrIm, an Immunopeptidomics tool for the Mid-Throughput era. This is a semi-automated workflow involving the KingFisher platform to isolate immunopeptidomes using anti-HLA antibodies coupled to a hyper-porous magnetic protein A microbead, a variable window data independent acquisition (DIA) method and the ability to run up to 12 samples in parallel. Using this workflow, we were able to concordantly identify and quantify ~400 - 13000 unique peptides from 5e5 - 5e7 cells, respectively. Overall, we propose that the application of this workflow will be crucial for the future of immunopeptidome profiling, especially for mid-size cohorts and comparative immunopeptidomics studies. |
format | Online Article Text |
id | pubmed-10272402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102724022023-06-17 SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics Lim Kam Sian, Terry C. C. Goncalves, Gabriel Steele, Joel R. Shamekhi, Tima Bramberger, Liesl Jin, Dongbin Shahbazy, Mohammad Purcell, Anthony W. Ramarathinam, Sri Stoychev, Stoyan Faridi, Pouya Front Immunol Immunology Human leukocyte antigen (HLA) molecules play a crucial role in directing adaptive immune responses based on the nature of their peptide ligands, collectively coined the immunopeptidome. As such, the study of HLA molecules has been of major interest in the development of cancer immunotherapies such as vaccines and T-cell therapies. Hence, a comprehensive understanding and profiling of the immunopeptidome is required to foster the growth of these personalised solutions. We herein describe SAPrIm, an Immunopeptidomics tool for the Mid-Throughput era. This is a semi-automated workflow involving the KingFisher platform to isolate immunopeptidomes using anti-HLA antibodies coupled to a hyper-porous magnetic protein A microbead, a variable window data independent acquisition (DIA) method and the ability to run up to 12 samples in parallel. Using this workflow, we were able to concordantly identify and quantify ~400 - 13000 unique peptides from 5e5 - 5e7 cells, respectively. Overall, we propose that the application of this workflow will be crucial for the future of immunopeptidome profiling, especially for mid-size cohorts and comparative immunopeptidomics studies. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272402/ /pubmed/37334365 http://dx.doi.org/10.3389/fimmu.2023.1107576 Text en Copyright © 2023 Lim Kam Sian, Goncalves, Steele, Shamekhi, Bramberger, Jin, Shahbazy, Purcell, Ramarathinam, Stoychev and Faridi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Lim Kam Sian, Terry C. C. Goncalves, Gabriel Steele, Joel R. Shamekhi, Tima Bramberger, Liesl Jin, Dongbin Shahbazy, Mohammad Purcell, Anthony W. Ramarathinam, Sri Stoychev, Stoyan Faridi, Pouya SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title | SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title_full | SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title_fullStr | SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title_full_unstemmed | SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title_short | SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics |
title_sort | saprim, a semi-automated protocol for mid-throughput immunopeptidomics |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272402/ https://www.ncbi.nlm.nih.gov/pubmed/37334365 http://dx.doi.org/10.3389/fimmu.2023.1107576 |
work_keys_str_mv | AT limkamsianterrycc saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT goncalvesgabriel saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT steelejoelr saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT shamekhitima saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT brambergerliesl saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT jindongbin saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT shahbazymohammad saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT purcellanthonyw saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT ramarathinamsri saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT stoychevstoyan saprimasemiautomatedprotocolformidthroughputimmunopeptidomics AT faridipouya saprimasemiautomatedprotocolformidthroughputimmunopeptidomics |